Clinical Trials
7
Active:3
Completed:4
Trial Phases
2 Phases
Phase 1:6
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (85.7%)Phase 2
1 (14.3%)VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma
Phase 1
Active, not recruiting
- Conditions
- Recurrent Glioblastoma
- First Posted Date
- 2018-11-21
- Last Posted Date
- 2022-10-20
- Lead Sponsor
- Vaximm GmbH
- Target Recruit Count
- 30
- Registration Number
- NCT03750071
- Locations
- 🇩🇪
Neurology Clinic and National Center for Tumor Diseases, Heidelberg, Germany
🇩🇪Neurology Clinic, Mannheim, Germany
VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma
- First Posted Date
- 2016-03-24
- Last Posted Date
- 2018-10-19
- Lead Sponsor
- Vaximm GmbH
- Target Recruit Count
- 14
- Registration Number
- NCT02718443
- Locations
- 🇩🇪
Neurology Clinic and National Center for Tumor Diseases, Heidelberg, Germany
VXM01 Phase I Study in Patients With Metastatic Colorectal Cancer With Liver Metastasis
- First Posted Date
- 2016-03-24
- Last Posted Date
- 2018-10-19
- Lead Sponsor
- Vaximm GmbH
- Target Recruit Count
- 6
- Registration Number
- NCT02718430
- Locations
- 🇩🇪
National Center of Tumor Diseases, Heidelberg, Germany
VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer
Phase 1
Completed
- Conditions
- Stage IV Pancreatic Cancer
- First Posted Date
- 2011-12-06
- Last Posted Date
- 2015-06-08
- Lead Sponsor
- Vaximm GmbH
- Target Recruit Count
- 72
- Registration Number
- NCT01486329
- Locations
- 🇩🇪
Clinic of General Surgery, Heidelberg, Germany
News
No news found